Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Overview

NASDAQ:HALO - US40637H1095 - Common Stock

73.15 USD
+0.34 (+0.47%)
Last: 8/29/2025, 9:26:58 PM
73.4 USD
+0.25 (+0.34%)
After Hours: 8/29/2025, 9:26:58 PM

HALO Key Statistics, Chart & Performance

Key Statistics
52 Week High74.07
52 Week Low42.01
Market Cap8.56B
Shares116.97M
Float115.60M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)5.18
PE14.12
Fwd PE9.06
Earnings (Next)10-29 2025-10-29/amc
IPO01-30 2003-01-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


HALO short term performance overview.The bars show the price performance of HALO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

HALO long term performance overview.The bars show the price performance of HALO in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of HALO is 73.15 USD. In the past month the price increased by 23.94%. In the past year, price increased by 14.57%.

HALOZYME THERAPEUTICS INC / HALO Daily stock chart

HALO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About HALO

Company Profile

HALO logo image Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Company Info

HALOZYME THERAPEUTICS INC

12390 El Camino Real

San Diego CALIFORNIA 92121-1345 US

CEO: Helen I. Torley

Employees: 350

HALO Company Website

HALO Investor Relations

Phone: 18587948889

HALOZYME THERAPEUTICS INC / HALO FAQ

What is the stock price of HALOZYME THERAPEUTICS INC today?

The current stock price of HALO is 73.15 USD. The price increased by 0.47% in the last trading session.


What is the ticker symbol for HALOZYME THERAPEUTICS INC stock?

The exchange symbol of HALOZYME THERAPEUTICS INC is HALO and it is listed on the Nasdaq exchange.


On which exchange is HALO stock listed?

HALO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HALOZYME THERAPEUTICS INC stock?

16 analysts have analysed HALO and the average price target is 72.93 USD. This implies a price decrease of -0.3% is expected in the next year compared to the current price of 73.15. Check the HALOZYME THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HALOZYME THERAPEUTICS INC worth?

HALOZYME THERAPEUTICS INC (HALO) has a market capitalization of 8.56B USD. This makes HALO a Mid Cap stock.


How many employees does HALOZYME THERAPEUTICS INC have?

HALOZYME THERAPEUTICS INC (HALO) currently has 350 employees.


What are the support and resistance levels for HALOZYME THERAPEUTICS INC (HALO) stock?

HALOZYME THERAPEUTICS INC (HALO) has a support level at 73.14 and a resistance level at 73.16. Check the full technical report for a detailed analysis of HALO support and resistance levels.


Is HALOZYME THERAPEUTICS INC (HALO) expected to grow?

The Revenue of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 31.57% in the next year. Check the estimates tab for more information on the HALO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HALOZYME THERAPEUTICS INC (HALO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HALOZYME THERAPEUTICS INC (HALO) stock pay dividends?

HALO does not pay a dividend.


When does HALOZYME THERAPEUTICS INC (HALO) report earnings?

HALOZYME THERAPEUTICS INC (HALO) will report earnings on 2025-10-29, after the market close.


What is the Price/Earnings (PE) ratio of HALOZYME THERAPEUTICS INC (HALO)?

The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 14.12. This is based on the reported non-GAAP earnings per share of 5.18 and the current share price of 73.15 USD. Check the full fundamental report for a full analysis of the valuation metrics for HALO.


What is the Short Interest ratio of HALOZYME THERAPEUTICS INC (HALO) stock?

The outstanding short interest for HALOZYME THERAPEUTICS INC (HALO) is 8.15% of its float. Check the ownership tab for more information on the HALO short interest.


HALO Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 82.06% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HALO Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to HALO. HALO scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HALO Financial Highlights

Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 5.18. The EPS increased by 58.41% compared to the year before.


Industry RankSector Rank
PM (TTM) 47.28%
ROA 27.13%
ROE 167.48%
Debt/Equity 4.54
Chartmill High Growth Momentum
EPS Q2Q%69.23%
Sales Q2Q%40.79%
EPS 1Y (TTM)58.41%
Revenue 1Y (TTM)34.97%

HALO Forecast & Estimates

16 analysts have analysed HALO and the average price target is 72.93 USD. This implies a price decrease of -0.3% is expected in the next year compared to the current price of 73.15.

For the next year, analysts expect an EPS growth of 47.96% and a revenue growth 31.57% for HALO


Analysts
Analysts73.75
Price Target72.93 (-0.3%)
EPS Next Y47.96%
Revenue Next Year31.57%

HALO Ownership

Ownership
Inst Owners100.38%
Ins Owners0.82%
Short Float %8.15%
Short Ratio4.55